GlassScriptPhysician profile
Charles D Hernandez
NPI 1942213103
$7,401.43
in general payments reported to CMS, 2019-2025
39 companies · $603 in 2025
The $603 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,985 · 2020: $971 · 2021: $1,033 · 2022: $822 · 2023: $917 · 2024: $1,070 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,590.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,093.88 | 2020-2025 | |
| Pfizer INC. | $899.69 | 2019-2025 | |
| Lilly USA, LLC | $491.18 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $460.41 | 2019-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $379.57 | 2019-2025 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $367.78 | 2019-2024 | |
| Allergan, INC. | $340.79 | 2019-2020 | |
| Novo Nordisk INC | $320.21 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $315.56 | 2019-2024 | Nuedexta, Rexulti |
| Amarin Pharma, INC. | $300.47 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $298.14 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $288.48 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $226.28 | 2019-2023 | |
| Avanir Pharmaceuticals, INC. | $216.08 | 2019-2022 | |
| Glaxosmithkline, LLC. | $170.39 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.